npj Breast Cancer

Table 1 Patient and tumor characteristics for the study population

From: Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer

		Treatment arm				Total
		CMF		CEF
		N	Col%	N	Col%	N	Col%
		595		545		1140
Age	< 50	428	72	391	72	819	72
	≥ 50	167	28	154	28	321	28
Menopausal status	Premenopausal	486	82	444	81	929	81
Menopausal status	Postmenopausal	109	18	101	19	211	19
Tumor size	≤ 2 cm	240	40	199	37	439	39
	> 2, ≤ 5 cm	301	51	289	53	590	52
	> 5 cm	42	7	37	7	79	7
	Unknown	12	2	20	4	32	3
Nodal status	Negative	121	20	123	23	244	21
	1-3 positive LN	262	44	234	43	496	44
	≥ 4 positive LN	212	36	188	35	400	35
Malignancy Grade	I	47	8	34	6	81	7
Malignancy Grade	II	244	41	227	42	471	41
	III	274	46	260	48	534	47
	Not graded	30	5	24	4	54	5
ER status	Positive	221	37	202	37	423	37
	Negative	247	42	221	41	468	41
	Unknown	127	21	122	22	249	22
HER2 status	Positive	162	27	152	28	312	27
	Negative	433	73	393	72	826	73
Trial	MA.5	233	39	221	41	454	40
	DBCG 89D	362	61	324	59	686	60

Back to article page

Search

Advanced search

Quick links